These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 1280575)

  • 1. Management of non-insulin-dependent diabetes mellitus.
    Lefèbvre PJ; Scheen AJ
    Drugs; 1992; 44 Suppl 3():29-38. PubMed ID: 1280575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes.
    Scheen AJ; Castillo MJ; Lefèbvre PJ
    Acta Clin Belg; 1993; 48(4):259-68. PubMed ID: 8212978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.
    Josse RG
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S167-72. PubMed ID: 8529510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
    Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
    J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. alpha-Glucosidase inhibitors in diabetes: efficacy in NIDDM subjects.
    Toeller M
    Eur J Clin Invest; 1994 Aug; 24 Suppl 3():31-5. PubMed ID: 8001625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).
    Wolffenbuttel BH; van Haeften TW
    Drugs; 1995 Aug; 50(2):263-88. PubMed ID: 8521759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
    Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH; Wolever TM
    Ann Intern Med; 1994 Dec; 121(12):928-35. PubMed ID: 7734015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative tolerability profiles of oral antidiabetic agents.
    Krentz AJ; Ferner RE; Bailey CJ
    Drug Saf; 1994 Oct; 11(4):223-41. PubMed ID: 7848543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.
    Santeusanio F; Compagnucci P
    Drug Saf; 1994 Dec; 11(6):432-44. PubMed ID: 7727053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone.
    Hanefeld M; Fischer S; Schulze J; Spengler M; Wargenau M; Schollberg K; Fücker K
    Diabetes Care; 1991 Aug; 14(8):732-7. PubMed ID: 1954810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with acarbose as first line therapy in NIDDM.
    Fölsch UR
    Clin Invest Med; 1995 Aug; 18(4):312-7. PubMed ID: 8549018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials.
    Scheen AJ
    Diabetes Metab; 1998 Sep; 24(4):311-20. PubMed ID: 9805641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral antidiabetic agents. A guide to selection.
    Scheen AJ; Lefèbvre PJ
    Drugs; 1998 Feb; 55(2):225-36. PubMed ID: 9506242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments.
    Scheen AJ
    Drugs; 1997 Sep; 54(3):355-68. PubMed ID: 9279500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic treatment options for non-insulin-dependent diabetes mellitus.
    Tan GH; Nelson RL
    Mayo Clin Proc; 1996 Aug; 71(8):763-8. PubMed ID: 8691897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with acarbose: results of a Canadian multicentre study.
    Rodger NW; Chiasson JL; Josse RG; Hunt JA; Palmason C; Ross SA; Ryan EA; Tan MH; Wolever TM
    Clin Invest Med; 1995 Aug; 18(4):318-24. PubMed ID: 8549019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.
    Coniff RF; Shapiro JA; Seaton TB
    Arch Intern Med; 1994 Nov; 154(21):2442-8. PubMed ID: 7979840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of intestinal alpha-glucosidase inhibition on postprandial glucose, pancreatic and gut hormone responses and fasting serum lipids in diabetics on sulphonylureas.
    Uttenthal LO; Ukponmwan OO; Wood SM; Ghiglione M; Ghatei MA; Trayner IM; Bloom SR
    Diabet Med; 1986 Mar; 3(2):155-60. PubMed ID: 2951158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors.
    Lebovitz HE
    Drugs; 1992; 44 Suppl 3():21-8. PubMed ID: 1280574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.